The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Paclitaxel Drug Market Research Report 2025
Synopsis
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
The global Paclitaxel Drug market was valued at US$ 117.6 million in 2023 and is anticipated to reach US$ 139.3 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paclitaxel Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paclitaxel Drug.
Report Scope
The Paclitaxel Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Paclitaxel Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paclitaxel Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Luye Pharma
CSPC Company
Celgene
Jiangsu Hengrui
Bristol-Myers Squibb
Pfizer
Teva
Mylan
Novartis
Segment by Type
30mg
100mg
Segment by Application
Hospital
Drugs Store
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Paclitaxel Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Paclitaxel Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
The global Paclitaxel Drug market was valued at US$ 117.6 million in 2023 and is anticipated to reach US$ 139.3 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Paclitaxel Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paclitaxel Drug.
Report Scope
The Paclitaxel Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Paclitaxel Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paclitaxel Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Luye Pharma
CSPC Company
Celgene
Jiangsu Hengrui
Bristol-Myers Squibb
Pfizer
Teva
Mylan
Novartis
Segment by Type
30mg
100mg
Segment by Application
Hospital
Drugs Store
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Paclitaxel Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Paclitaxel Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Paclitaxel Drug Market Overview
1.1 Product Overview and Scope of Paclitaxel Drug
1.2 Paclitaxel Drug Segment by Type
1.2.1 Global Paclitaxel Drug Market Value Comparison by Type (2024-2030)
1.2.2 30mg
1.2.3 100mg
1.3 Paclitaxel Drug Segment by Application
1.3.1 Global Paclitaxel Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drugs Store
1.4 Global Paclitaxel Drug Market Size Estimates and Forecasts
1.4.1 Global Paclitaxel Drug Revenue 2019-2030
1.4.2 Global Paclitaxel Drug Sales 2019-2030
1.4.3 Global Paclitaxel Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Paclitaxel Drug Market Competition by Manufacturers
2.1 Global Paclitaxel Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Paclitaxel Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Paclitaxel Drug Average Price by Manufacturers (2019-2024)
2.4 Global Paclitaxel Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Paclitaxel Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paclitaxel Drug, Product Type & Application
2.7 Paclitaxel Drug Market Competitive Situation and Trends
2.7.1 Paclitaxel Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Paclitaxel Drug Players Market Share by Revenue
2.7.3 Global Paclitaxel Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Paclitaxel Drug Retrospective Market Scenario by Region
3.1 Global Paclitaxel Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Paclitaxel Drug Global Paclitaxel Drug Sales by Region: 2019-2030
3.2.1 Global Paclitaxel Drug Sales by Region: 2019-2024
3.2.2 Global Paclitaxel Drug Sales by Region: 2025-2030
3.3 Global Paclitaxel Drug Global Paclitaxel Drug Revenue by Region: 2019-2030
3.3.1 Global Paclitaxel Drug Revenue by Region: 2019-2024
3.3.2 Global Paclitaxel Drug Revenue by Region: 2025-2030
3.4 North America Paclitaxel Drug Market Facts & Figures by Country
3.4.1 North America Paclitaxel Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Paclitaxel Drug Sales by Country (2019-2030)
3.4.3 North America Paclitaxel Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paclitaxel Drug Market Facts & Figures by Country
3.5.1 Europe Paclitaxel Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Paclitaxel Drug Sales by Country (2019-2030)
3.5.3 Europe Paclitaxel Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paclitaxel Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Paclitaxel Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Paclitaxel Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Paclitaxel Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Paclitaxel Drug Market Facts & Figures by Country
3.7.1 Latin America Paclitaxel Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Paclitaxel Drug Sales by Country (2019-2030)
3.7.3 Latin America Paclitaxel Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Paclitaxel Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Paclitaxel Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Paclitaxel Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Paclitaxel Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paclitaxel Drug Sales by Type (2019-2030)
4.1.1 Global Paclitaxel Drug Sales by Type (2019-2024)
4.1.2 Global Paclitaxel Drug Sales by Type (2025-2030)
4.1.3 Global Paclitaxel Drug Sales Market Share by Type (2019-2030)
4.2 Global Paclitaxel Drug Revenue by Type (2019-2030)
4.2.1 Global Paclitaxel Drug Revenue by Type (2019-2024)
4.2.2 Global Paclitaxel Drug Revenue by Type (2025-2030)
4.2.3 Global Paclitaxel Drug Revenue Market Share by Type (2019-2030)
4.3 Global Paclitaxel Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Paclitaxel Drug Sales by Application (2019-2030)
5.1.1 Global Paclitaxel Drug Sales by Application (2019-2024)
5.1.2 Global Paclitaxel Drug Sales by Application (2025-2030)
5.1.3 Global Paclitaxel Drug Sales Market Share by Application (2019-2030)
5.2 Global Paclitaxel Drug Revenue by Application (2019-2030)
5.2.1 Global Paclitaxel Drug Revenue by Application (2019-2024)
5.2.2 Global Paclitaxel Drug Revenue by Application (2025-2030)
5.2.3 Global Paclitaxel Drug Revenue Market Share by Application (2019-2030)
5.3 Global Paclitaxel Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Luye Pharma
6.1.1 Luye Pharma Corporation Information
6.1.2 Luye Pharma Description and Business Overview
6.1.3 Luye Pharma Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Luye Pharma Paclitaxel Drug Product Portfolio
6.1.5 Luye Pharma Recent Developments/Updates
6.2 CSPC Company
6.2.1 CSPC Company Corporation Information
6.2.2 CSPC Company Description and Business Overview
6.2.3 CSPC Company Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CSPC Company Paclitaxel Drug Product Portfolio
6.2.5 CSPC Company Recent Developments/Updates
6.3 Celgene
6.3.1 Celgene Corporation Information
6.3.2 Celgene Description and Business Overview
6.3.3 Celgene Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celgene Paclitaxel Drug Product Portfolio
6.3.5 Celgene Recent Developments/Updates
6.4 Jiangsu Hengrui
6.4.1 Jiangsu Hengrui Corporation Information
6.4.2 Jiangsu Hengrui Description and Business Overview
6.4.3 Jiangsu Hengrui Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Jiangsu Hengrui Paclitaxel Drug Product Portfolio
6.4.5 Jiangsu Hengrui Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Paclitaxel Drug Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer Paclitaxel Drug Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Paclitaxel Drug Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mylan Paclitaxel Drug Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Paclitaxel Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novartis Paclitaxel Drug Product Portfolio
6.9.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paclitaxel Drug Industry Chain Analysis
7.2 Paclitaxel Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paclitaxel Drug Production Mode & Process
7.4 Paclitaxel Drug Sales and Marketing
7.4.1 Paclitaxel Drug Sales Channels
7.4.2 Paclitaxel Drug Distributors
7.5 Paclitaxel Drug Customers
8 Paclitaxel Drug Market Dynamics
8.1 Paclitaxel Drug Industry Trends
8.2 Paclitaxel Drug Market Drivers
8.3 Paclitaxel Drug Market Challenges
8.4 Paclitaxel Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
